A Multicenter, Open-label, Randomized, Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma

Trial Profile

A Multicenter, Open-label, Randomized, Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Fosbretabulin (Primary) ; Carboplatin; Paclitaxel
  • Indications Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FACT
  • Sponsors OXiGENE
  • Most Recent Events

    • 10 Jun 2013 The results of the FACT study form the basis of OXiGENE's Marketing Application Authorization (MAA) application with the European Medicine Agency (EMA), according to an OXiGENE media release.
    • 10 Jun 2013 Final results published in Thyroid journal, according to an OXiGENE media release.
    • 09 Sep 2012 Diagnostic pathology data were presented at the 36th Annual Meeting of the European Thyroid Association, according to an OXiGENE media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top